The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Truist Securities on January 29, 2025. The analyst firm set a price target for $18.00 expecting LRMR to rise to within 12 months (a possible 467.43% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Larimar Therapeutics (NASDAQ:LRMR) was provided by Truist Securities, and Larimar Therapeutics initiated their buy rating.

The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.

There is no last downgrade for Larimar Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a initiated with a price target of $0.00 to $18.00. The current price Larimar Therapeutics (LRMR) is trading at is $3.17, which is within the analyst’s predicted range.